There's a reputational risk there to the industry.
Quite honestly, in addition to considerations around Vanessa's Law, the real issue there is Health Canada getting out and inspecting.
As I said in my presentation, the debates around Vanessa's Law are.... Again, we appreciate the interest, but the real challenges we have right now are operational within Health Canada and the current regulatory regime. That includes, as the AG identified, the need to be doing more post-market inspections. In order to be able to do that, there is a need to put a lighter touch on the front end, bringing products onto the market.
For me, Vanessa's Law is a bit of a non-issue here, quite honestly, but the urgency around those regulatory challenges is not. It is why companies are not introducing new products in Canada to the degree they might be, and it is why some players are staying out of the country.